Symbols / BIOR
BIOR Chart
About
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 994.99K |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | -36.43 | Cash/sh | — | Dividend Yield | — |
| Payout | 0.00% | Employees | 58 | IPO | — |
| P/E | 0.61 | Forward P/E | -0.02 | PEG | — |
| P/S | — | P/B | -0.01 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 0.36 | EPS next Y | -11.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-11-14 16:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.52M |
| Shs Float | — | Short Float | 8.58% | Short Ratio | 2.37 |
| Short Interest | — | 52W High | 0.38 | 52W Low | 0.15 |
| Beta | — | Avg Volume | 0.00 | Volume | 169.45K |
| Target Price | $34.00 | Recom | None | Prev Close | $0.22 |
| Price | $0.22 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.00
Mean price target
2. Current target
$0.22
Latest analyst target
3. DCF / Fair value
$5.40
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$0.22
Low
$23.00
High
$45.00
Mean
$34.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-18 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-22 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-01-02 | reit | HC Wainwright & Co. | Buy → Buy | $50 |
| 2023-10-02 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $65 |
| 2023-07-27 | reit | HC Wainwright & Co. | Buy → Buy | $65 |
| 2023-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $65 |
| 2023-01-10 | main | HC Wainwright & Co. | — → Buy | $65 |
- Biora's Fresh Start: Restructuring Success Fuels BioJet Platform Development - Stock Titan Mon, 31 Mar 2025 07
- BIOR Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- Biora Therapeutics News: Latest Updates on the Private BioJet Developer - Meyka ue, 06 May 2025 07
- Why Is Biora Therapeutics (BIOR) Stock Up 12% Today? - InvestorPlace Wed, 11 Jan 2023 08
- Biora Therapeutics Files for Bankruptcy to Restructure - Nasdaq Mon, 30 Dec 2024 08
- Biora Therapeutics (BIOR) Stock Price, News & Analysis $BIOR - MarketBeat Sat, 14 May 2022 18
- Biora Therapeutics to be delisted from Nasdaq - Investing.com ue, 10 Dec 2024 08
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biora Therapeutics, Inc. - BIOR - PR Newswire Fri, 03 Nov 2023 07
- Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News Fri, 21 Feb 2025 08
- 3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 - Yahoo Finance Wed, 24 May 2023 07
- Bio-polypropylene Market Size & Forecast [Latest] - MarketsandMarkets hu, 30 Jan 2025 03
- Highbridge Capital Management's Strategic Acquisition of Biora T - GuruFocus hu, 14 Nov 2024 08
- Save the Date – The EIFAAC 2026 International Symposium will be held in Riga, Latvia, on 5-7 October 2026 - Food and Agriculture Organization Wed, 17 Dec 2025 08
- BIOR Stock Starts Trading as Progenity’s Rebrand Takes Shape. What to Know. - InvestorPlace ue, 10 May 2022 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - Nasdaq Fri, 01 Dec 2023 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 12500 | — | — | Stock Award(Grant) at price 0.00 per share. | POWELL LYNNE M | Director | — | 2024-06-05 00:00:00 | D |
| 1 | 12500 | — | — | Stock Award(Grant) at price 0.00 per share. | KOTZIN BRIAN L | Director | — | 2024-06-05 00:00:00 | D |
| 2 | 12500 | — | — | Stock Award(Grant) at price 0.00 per share. | ALTER JEFFREY D | Director | — | 2024-06-05 00:00:00 | D |
| 3 | 12500 | — | — | Stock Award(Grant) at price 0.00 per share. | HOWE JILL ANN | Director | — | 2024-06-05 00:00:00 | D |
| 4 | 230000 | — | — | Stock Award(Grant) at price 0.00 per share. | NEUMANN CLARKE WILLIAM | General Counsel | — | 2024-02-15 00:00:00 | D |
| 5 | 325000 | — | — | Stock Award(Grant) at price 0.00 per share. | D'ESPARBES ERIC | Chief Financial Officer | — | 2024-02-15 00:00:00 | D |
| 6 | 819000 | — | — | Stock Award(Grant) at price 0.00 per share. | MOHANTY ADITYA P | Chief Executive Officer | — | 2024-02-15 00:00:00 | D |
| 7 | 9235281 | — | — | Stock Award(Grant) at price 0.00 per share. | ATHYRIUM OPPORTUNITIES III CO-INVEST 1 L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2023-09-18 00:00:00 | I |
| 8 | 210175 | — | — | Stock Award(Grant) at price 0.00 per share. | NEUMANN CLARKE WILLIAM | General Counsel | — | 2023-08-15 00:00:00 | D |
| 9 | 219650 | — | — | Stock Award(Grant) at price 0.00 per share. | D'ESPARBES ERIC | Chief Financial Officer | — | 2023-08-15 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 13.02K | 178.27K | -36.08K |
| TaxRateForCalcs | 0.00 | 0.01 | 0.00 |
| NormalizedEBITDA | -132.06M | -58.26M | -110.41M |
| TotalUnusualItems | 18.00M | 20.90M | -54.16M |
| TotalUnusualItemsExcludingGoodwill | 18.00M | 20.90M | -54.16M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -124.33M | -48.83M | -178.52M |
| ReconciledDepreciation | 555.00K | 907.00K | 1.44M |
| ReconciledCostOfRevenue | 0.00 | ||
| EBITDA | -114.05M | -37.35M | -164.57M |
| EBIT | -114.61M | -38.26M | -166.00M |
| NetInterestIncome | -9.81M | -10.99M | -12.64M |
| InterestExpense | 9.81M | 10.99M | 12.64M |
| NormalizedIncome | -142.32M | -69.56M | -124.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -124.11M | -38.16M | -247.41M |
| TotalExpenses | 67.15M | 62.09M | 119.08M |
| TotalOperatingIncomeAsReported | -67.14M | -61.78M | -117.84M |
| DilutedAverageShares | 1.58M | 1.22K | 384.62K |
| BasicAverageShares | 1.58M | 1.22K | 384.62K |
| DilutedEPS | -78.70 | -31.25K | -642.50 |
| BasicEPS | -78.70 | -31.25K | -642.50 |
| DilutedNIAvailtoComStockholders | -124.11M | -38.16M | -247.41M |
| NetIncomeCommonStockholders | -124.11M | -38.16M | -247.41M |
| NetIncome | -124.11M | -38.16M | -247.41M |
| NetIncomeIncludingNoncontrollingInterests | -124.11M | -38.16M | -247.41M |
| NetIncomeDiscontinuousOperations | 219.00K | 10.67M | -68.89M |
| NetIncomeContinuousOperations | -124.33M | -48.83M | -178.52M |
| TaxProvision | -90.00K | -420.00K | -119.00K |
| PretaxIncome | -124.42M | -49.25M | -178.64M |
| OtherIncomeExpense | -47.47M | 23.52M | -48.17M |
| OtherNonOperatingIncomeExpenses | -65.47M | 2.62M | 5.99M |
| GainOnSaleOfSecurity | 18.00M | 20.90M | -54.16M |
| NetNonOperatingInterestIncomeExpense | -9.81M | -10.99M | -12.64M |
| TotalOtherFinanceCost | 12.64M | ||
| InterestExpenseNonOperating | 9.81M | 10.99M | 12.64M |
| OperatingIncome | -67.14M | -61.78M | -117.84M |
| OperatingExpense | 67.15M | 62.09M | 119.08M |
| ResearchAndDevelopment | 29.84M | 24.05M | 45.78M |
| SellingGeneralAndAdministration | 37.31M | 38.04M | 73.30M |
| SellingAndMarketingExpense | 4.76M | ||
| GeneralAndAdministrativeExpense | 68.54M | ||
| OtherGandA | 68.54M | ||
| GrossProfit | 1.25M | ||
| CostOfRevenue | 0.00 | ||
| TotalRevenue | 4.00K | 305.00K | 1.25M |
| OperatingRevenue | 4.00K | 305.00K | 1.25M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TreasurySharesNumber | 73.73K | 17.03K | 15.46K |
| OrdinarySharesNumber | 2.78M | 892.85K | 727.49K |
| ShareIssued | 2.86M | 909.88K | 742.95K |
| NetDebt | 30.50M | 97.33M | 37.99M |
| TotalDebt | 47.43M | 129.31M | 126.40M |
| TangibleBookValue | -107.49M | -108.36M | -91.05M |
| InvestedCapital | -55.71M | 25.52M | 41.42M |
| WorkingCapital | -43.90M | 14.81M | 37.17M |
| NetTangibleAssets | -107.49M | -108.36M | -91.05M |
| CapitalLeaseObligations | 1.71M | 1.49M | 12.00K |
| CommonStockEquity | -101.42M | -102.29M | -84.98M |
| TotalCapitalization | -57.69M | 25.52M | 41.42M |
| TotalEquityGrossMinorityInterest | -101.42M | -102.29M | -84.98M |
| StockholdersEquity | -101.42M | -102.29M | -84.98M |
| TreasuryStock | 19.08M | 19.08M | 19.08M |
| RetainedEarnings | -950.96M | -826.84M | -788.69M |
| AdditionalPaidInCapital | 868.59M | 743.63M | 722.78M |
| CapitalStock | 25.00K | 8.00K | 6.00K |
| CommonStock | 25.00K | 8.00K | 6.00K |
| TotalLiabilitiesNetMinorityInterest | 132.64M | 155.81M | 193.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 69.66M | 132.51M | 132.21M |
| OtherNonCurrentLiabilities | 2.21M | 4.09M | 5.62M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | ||
| DerivativeProductLiabilities | 22.90M | 0.00 | 0.00 |
| NonCurrentAccruedExpenses | 0.00 | 192.00K | |
| LongTermDebtAndCapitalLeaseObligation | 44.55M | 128.41M | 126.39M |
| LongTermCapitalLeaseObligation | 818.00K | 601.00K | 0.00 |
| LongTermDebt | 43.74M | 127.81M | 126.39M |
| CurrentLiabilities | 62.97M | 23.30M | 61.61M |
| OtherCurrentLiabilities | 43.05M | 5.59M | 21.74M |
| CurrentDeferredLiabilities | 542.00K | 47.00K | 301.00K |
| CurrentDeferredRevenue | 542.00K | 47.00K | 301.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.87M | 893.00K | 12.00K |
| CurrentCapitalLeaseObligation | 896.00K | 893.00K | 12.00K |
| CurrentDebt | 1.98M | ||
| OtherCurrentBorrowings | 1.98M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.37M | 1.72M | 6.89M |
| PayablesAndAccruedExpenses | 15.14M | 15.05M | 32.66M |
| CurrentAccruedExpenses | 12.29M | 11.45M | 23.95M |
| InterestPayable | 173.00K | 890.00K | 802.00K |
| Payables | 2.84M | 3.61M | 8.71M |
| AccountsPayable | 2.84M | 3.61M | 8.71M |
| TotalAssets | 31.21M | 53.52M | 108.84M |
| TotalNonCurrentAssets | 12.14M | 15.41M | 10.06M |
| OtherNonCurrentAssets | 302.00K | 201.00K | 326.00K |
| InvestmentsAndAdvances | 3.00M | 6.00M | 0.00 |
| OtherInvestments | 3.00M | 6.00M | 0.00 |
| GoodwillAndOtherIntangibleAssets | 6.07M | 6.07M | 6.07M |
| Goodwill | 6.07M | 6.07M | 6.07M |
| NetPPE | 2.77M | 3.14M | 3.67M |
| AccumulatedDepreciation | -2.11M | -4.00M | -5.62M |
| GrossPPE | 4.88M | 7.13M | 9.29M |
| ConstructionInProgress | 45.00K | 92.00K | 16.00K |
| OtherProperties | 2.04M | 2.44M | 2.69M |
| MachineryFurnitureEquipment | 1.99M | 3.85M | 6.15M |
| BuildingsAndImprovements | 803.00K | 750.00K | 437.00K |
| LandAndImprovements | 346.00K | ||
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 19.07M | 38.12M | 98.78M |
| OtherCurrentAssets | 587.00K | 565.00K | 1.11M |
| AssetsHeldForSaleCurrent | 0.00 | 2.60M | 2.49M |
| PrepaidAssets | 2.44M | 3.63M | 6.12M |
| Receivables | 830.00K | 828.00K | 653.00K |
| TaxesReceivable | 830.00K | 828.00K | 0.00 |
| AccountsReceivable | 0.00 | 653.00K | |
| CashCashEquivalentsAndShortTermInvestments | 15.21M | 30.49M | 88.40M |
| CashAndCashEquivalents | 15.21M | 30.49M | 88.40M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -48.60M | -65.21M | -168.34M |
| RepaymentOfDebt | 0.00 | -12.00K | -1.64M |
| IssuanceOfDebt | 10.00M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 18.14M | 9.01M | 46.78M |
| CapitalExpenditure | -103.00K | -792.00K | -855.00K |
| InterestPaidSupplementalData | 2.28M | 5.87M | 7.54M |
| IncomeTaxPaidSupplementalData | 18.00K | 31.00K | 367.00K |
| EndCashPosition | 15.21M | 30.49M | 88.40M |
| BeginningCashPosition | 30.49M | 88.40M | 92.08M |
| ChangesInCash | -15.28M | -57.91M | -3.68M |
| FinancingCashFlow | 30.78M | 7.30M | 165.05M |
| CashFromDiscontinuedFinancingActivities | 0.00 | -1.78M | |
| CashFlowFromContinuingFinancingActivities | 30.78M | 7.30M | 166.83M |
| NetOtherFinancingCharges | -5.36M | -5.12M | -3.75M |
| ProceedsFromStockOptionExercised | 8.00M | 3.42M | 125.45M |
| NetPreferredStockIssuance | 0.00 | ||
| PreferredStockIssuance | 0.00 | ||
| NetCommonStockIssuance | 18.14M | 9.01M | 46.78M |
| CommonStockIssuance | 18.14M | 9.01M | 46.78M |
| NetIssuancePaymentsOfDebt | 10.00M | -12.00K | -1.64M |
| NetLongTermDebtIssuance | 10.00M | -12.00K | -1.64M |
| LongTermDebtPayments | 0.00 | -12.00K | -1.64M |
| LongTermDebtIssuance | 10.00M | 0.00 | 0.00 |
| InvestingCashFlow | 2.44M | -792.00K | -1.24M |
| CashFromDiscontinuedInvestingActivities | 2.54M | 0.00 | -387.00K |
| CashFlowFromContinuingInvestingActivities | -92.00K | -792.00K | -855.00K |
| NetPPEPurchaseAndSale | -92.00K | -792.00K | -855.00K |
| SaleOfPPE | 11.00K | 0.00 | |
| PurchaseOfPPE | -103.00K | -792.00K | -855.00K |
| OperatingCashFlow | -48.50M | -64.42M | -167.49M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 1.76M | -27.15M |
| CashFlowFromContinuingOperatingActivities | -48.50M | -66.17M | -140.33M |
| ChangeInWorkingCapital | 8.62M | -4.65M | -25.86M |
| ChangeInOtherCurrentLiabilities | -1.88M | -1.72M | 4.41M |
| ChangeInOtherCurrentAssets | 0.00 | -158.00K | |
| ChangeInPayablesAndAccruedExpense | 9.51M | -5.49M | -31.52M |
| ChangeInAccruedExpense | 10.68M | -417.00K | -22.91M |
| ChangeInPayable | -1.17M | -5.07M | -8.61M |
| ChangeInAccountPayable | -1.17M | -5.07M | -8.69M |
| ChangeInTaxPayable | 0.00 | 79.00K | |
| ChangeInIncomeTaxPayable | 0.00 | 79.00K | |
| ChangeInPrepaidAssets | 998.00K | 3.39M | 1.40M |
| ChangeInReceivables | -2.00K | -828.00K | 0.00 |
| OtherNonCashItems | 1.38M | -9.25M | 70.46M |
| StockBasedCompensation | 16.48M | 7.80M | 11.96M |
| ProvisionandWriteOffofAssets | 0.00 | 979.00K | |
| AssetImpairmentCharge | 100.00K | 545.00K | 0.00 |
| DepreciationAmortizationDepletion | 555.00K | 907.00K | 1.44M |
| DepreciationAndAmortization | 555.00K | 907.00K | 1.44M |
| OperatingGainsLosses | 48.49M | -23.37M | 48.10M |
| GainLossOnInvestmentSecurities | -11.09M | -26.64M | 35.79M |
| GainLossOnSaleOfPPE | 15.00K | 543.00K | 99.00K |
| NetIncomeFromContinuingOperations | -124.11M | -38.16M | -247.41M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for BIOR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|